TUNE-401 gives Tune Therapeutics an early signal in the race for finite HBV therapy
Find out how Tune Therapeutics’ TUNE-401 data could reshape the chronic hepatitis B cure race and what risks remain for Phase 2.
Pharma & Biotech
Pharma & Biotech
Could AHB-137 set a new benchmark for HBV cure rates? Insights from AusperBio’s 24-week monotherapy trial
AusperBio Therapeutics, Inc. announced that its lead investigational product, AHB-137, achieved a 30% functional cure rate as a 24-week monotherapy in HBeAg-negative chronic hepatitis B patients already on stable nucleos(t)ide analogue therapy. The data, presented at HEP-DART 2025, showed that patients with baseline HBsAg 100–1,000 IU/mL reached this endpoint at Week 72 in the company’s